Top-Rated StocksTop-RatedNASDAQ:TRVI Trevi Therapeutics (TRVI) Stock Price, News & Analysis $14.95 -0.26 (-1.71%) Closing price 09/18/2026 04:00 PM EasternExtended Trading$14.96 +0.01 (+0.07%) As of 09/18/2026 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Trevi Therapeutics Stock (NASDAQ:TRVI) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Trevi Therapeutics alerts:Sign Up Key Stats Today's Range$14.81▼$15.3850-Day Range$14.95▼$19.0752-Week Range$8.04▼$20.22Volume2.14 million shsAverage Volume1.42 million shsMarket Capitalization$2.13 billionP/E RatioN/ADividend YieldN/APrice Target$27.08Consensus RatingBuy Company Overview Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing medicines for chronic cough and other conditions involving dysregulated sensory nerve activity. The company’s lead product candidate is Haduvio, an oral extended-release formulation of nalbuphine designed to reduce chronic cough through activity at opioid receptors. Trevi is studying Haduvio for chronic cough associated with idiopathic pulmonary fibrosis, a progressive lung disease, as well as refractory chronic cough, a condition in which coughing persists despite treatment of underlying causes. The company’s development programs are intended to address significant unmet needs for patients who have limited approved treatment options. Founded in 2011 and headquartered in New Haven, Connecticut, Trevi conducts clinical development activities primarily in the United States and through international studies. Jennifer Good serves as the company’s chief executive officer and has led its advancement of nalbuphine-based therapies.AI Generated. May Contain Errors. Read More Trevi Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks75th Percentile Overall ScoreTRVI MarketRank™: Trevi Therapeutics scored higher than 75% of companies evaluated by MarketBeat, and ranked 153rd out of 905 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.5 / 5Analyst RatingBuy Consensus RatingTrevi Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 strong buy ratings, 10 buy ratings, no hold ratings, and 1 sell rating.Upside PotentialTrevi Therapeutics has a consensus price target of $27.08, representing about 81.2% upside from its current price of $14.95.Amount of Analyst CoverageTrevi Therapeutics has been the subject of 9 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Trevi Therapeutics' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Trevi Therapeutics are expected to decrease in the coming year, from ($0.48) to ($0.62) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Trevi Therapeutics is -43.97, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Trevi Therapeutics is -43.97, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioTrevi Therapeutics has a P/B Ratio of 10.45. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Trevi Therapeutics' valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted9.96% of the float of Trevi Therapeutics has been sold short.Short Interest Ratio / Days to CoverTrevi Therapeutics has a short interest ratio ("days to cover") of 8.04.Change versus previous monthShort interest in Trevi Therapeutics has recently decreased by 5.10%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldTrevi Therapeutics does not currently pay a dividend.Dividend GrowthTrevi Therapeutics does not have a long track record of dividend growth. News and Social Media3.6 / 5News Sentiment0.77 News SentimentTrevi Therapeutics has a news sentiment score of 0.77. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.56 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 6 news articles for Trevi Therapeutics this week, compared to 3 articles on an average week.MarketBeat Follows3 people have added Trevi Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 50% compared to the previous 30 days. Company Ownership2.0 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Trevi Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $595,648.00 in company stock.Percentage Held by Insiders15.39% of the stock of Trevi Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions95.76% of the stock of Trevi Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Trevi Therapeutics' insider trading history. Receive TRVI Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Trevi Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. TRVI Stock News HeadlinesMichael Thomas Heffernan Sells 39,473 Shares of Trevi Therapeutics (NASDAQ:TRVI) StockSeptember 18 at 6:52 AM | insidertrades.comTrevi Therapeutics, Inc. (TRVI) Presents at Morgan Stanley 24th Annual Global Healthcare Conference TranscriptSeptember 15, 2026 | seekingalpha.comReady to give options a try? Your first trade (Ticker included) -INSIDETired of trying tactic after tactic when it comes to options trades... only to be met with market noise and stinging losses? Dave Aquino is giving away the exact 11-hour options strategy he uses in volatile markets. You get the plain English blueprint behind the strategy and the very same "rinse and repeat" ticker he's traded nearly 900 times with a 95.3% success rate. It's so simple to understand, you could trade it tomorrow.September 19 at 1:00 AM | Base Camp Trading (Ad)Raymond James Sticks to Its Buy Rating for Trevi Therapeutics (TRVI)September 5, 2026 | theglobeandmail.comTrevi Therapeutics (TRVI) Receives a New Rating from B. Riley SecuritiesSeptember 5, 2026 | theglobeandmail.comTrevi Therapeutics to Present at Multiple Healthcare and IPF Conferences in September 2026September 3, 2026 | quiverquant.comQTrevi Therapeutics to Participate in Upcoming September ConferencesSeptember 3, 2026 | globenewswire.comTrevi Therapeutics Announces Upcoming Presentations at the European Respiratory Society (ERS) Congress 2026August 26, 2026 | globenewswire.comSee More Headlines TRVI Stock Analysis - Frequently Asked Questions How have TRVI shares performed this year? Trevi Therapeutics' stock was trading at $12.52 at the start of the year. Since then, TRVI stock has increased by 19.4% and is now trading at $14.95. How were Trevi Therapeutics' earnings last quarter? Trevi Therapeutics, Inc. (NASDAQ:TRVI) released its quarterly earnings results on Thursday, August, 6th. The company reported ($0.11) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.11) by $0.00. Read the conference call transcript. When did Trevi Therapeutics IPO? Trevi Therapeutics (TRVI) raised $70 million in an initial public offering on Tuesday, May 7th 2019. The company issued 4,700,000 shares at a price of $14.00-$16.00 per share. SVB Leerink, Stifel and BMO Capital Markets acted as the underwriters for the IPO and Needham & Company was co-manager. Who are Trevi Therapeutics' major shareholders? Trevi Therapeutics' top institutional shareholders include BlackRock Inc. (7.86%), Wellington Management Group LLP (3.99%), Artia Global Partners LP (1.55%) and First Light Asset Management LLC (1.47%). Insiders that own company stock include David P Meeker, Thomas Sciascia, Jennifer L Good, Farrell Simon, Lisa Delfini and Michael Thomas Heffernan. View institutional ownership trends. How do I buy shares of Trevi Therapeutics? Shares of TRVI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Trevi Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Trevi Therapeutics investors own include JPMorgan Chase & Co. (JPM), Predictive Oncology (POAI), Ford Motor (F), Tesla (TSLA), Meta Platforms (META), Abbott Laboratories (ABT) and Bank of America (BAC). Company Calendar Last Earnings8/06/2026Today9/19/202610th Anniversary IPF Summit10/01/2026Next Earnings (Estimated)11/12/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (31m+) 1-Year History Sep 25 Dec 25 Mar 26 Jun 26 Sep 26 TRVI's financial health is in the Green zone, according to TradeSmith. TRVI has been in this zone for over 31 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Pharmaceuticals Sub-IndustryPharmaceuticals Current SymbolNASDAQ:TRVI CIK1563880 Webwww.trevitherapeutics.com Phone(203) 304-2499FaxN/AEmployees34Year Founded2011Price Target and Rating Average Price Target for Trevi Therapeutics$27.08 High Price Target$40.00 Low Price Target$16.00 Potential Upside/Downside+81.2%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage13 Analysts Profitability EPS (Trailing Twelve Months)($0.34) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$42.76 million Net MarginsN/A Pretax MarginN/A Return on Equity-23.59% Return on Assets-22.64% Debt Debt-to-Equity RatioN/A Current Ratio37.28 Quick Ratio37.28 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$1.43 per share Price / Book10.45Miscellaneous Outstanding Shares142,480,000Free Float120,549,000Market Cap$2.13 billion OptionableOptionable Beta1.04 Social Links The Best Nuclear Energy Stocks to BuyNuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.Get This Free Report This page (NASDAQ:TRVI) was last updated on 9/19/2026 by MarketBeat.com Staff. From Our PartnersThey didn't warn anyone in 1971. This time someone is warning you.On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredReady to give options a try? Your first trade (Ticker included) -INSIDETired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...Base Camp Trading | SponsoredHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...Stansberry Research | SponsoredHere’s Why Trump Won’t End The Iran WarTrump has called an Iran deal close 38 times since the war began, yet the fighting keeps flaring back up. O...Banyan Hill Publishing | SponsoredYour book is insideThe "Sucker's Bet" Most New Options Traders Fall For Most people who try options lose money the same way. ...Profits Run | SponsoredMILLIONAIRE MASTERCLASS INVITE: AltucherJames Altucher says Elon Musk is preparing an unprecedented project set to surface on September 25. Altuche...Paradigm Press | SponsoredBank of America: 'Digital Dollar Inevitable'Bank of America just revealed your expiration date. In their Bloomberg interview, they didn't just predict the...Decentralized Masters | SponsoredYour withdrawal order could cost you in taxesIf you have $2M or more saved, the 4% rule points to roughly $92,000 a year - but it's a single-variable answe...SmartAsset | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Trevi Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Trevi Therapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
